As PCMag's resident data journalist, I practically live in Microsoft Excel. I've learned that it's capable of far more than I ...

Dozens walked out of Julian Schnabel's new film. Here's what happened next Dietitians say you shouldn't take these vitamins in the morning US launches hundreds of combat vehicles from a massive ship ...

Refund fraud is no longer just opportunistic abuse of return policies. Instead, it has evolved into a structured underground marketplace where fraud techniques are packaged and sold like digital ...

In December, Howard Marks published an investment memo titled, “Is it a bubble?” that expressed some of his skepticism and reservations about artificial intelligence and the stock-market boom it had ...

Reps. Marjorie Taylor Greene (R-GA) and Thomas Massie (R-KY) talk with reporters in Washington, D.C., on May 7, 2024. (Allison Bailey / NurPhoto via AFP) ATLANTA (CN) — Voters in northwest Georgia are ...

Replimune Group beat estimated earnings by 7.000000000000001%, reporting an EPS of $-0.77 versus an estimate of $-0.83. Revenue was down $0 from the same period last year. The company missed on EPS by ...

Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

It was the subject of a recommendation downgrade from an analyst. Another pundit reiterated his neutral stance on the company. Rama based much of his new take on the company on the latest developments ...

A crucial meeting with a regulator didn't seem to go well. It was about a leading pipeline drug being developed by the company. The meeting was conducted with U.S. Food and Drug Administration (FDA) ...